519 / 1084
Historical Perspective (5)
Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study
(CROSS)
) trial
Large sample size
Most patients had adenocarcinoma, anatomically lower tumors
Chemotherapy regimen
(carboplatin/paclitaxel)
Van Hagen, P.; Hulshof, M.C.; van Lanschot, J.J.; Steyerberg, E.W.; van Berge Henegouwen, M.I.;
Wijnhoven, B.P.; Richel, D.J.; Nieuwenhuijzen, G.A.; Hospers, G.A.; Bonenkamp, J.J.; et al. Preoperative
chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med.
2012
, 366, 2074–2084
.
Lower RT dose
(41.4 Gy)
Doubling OS: 48.6 months vs. 24.0 months.
There was also no observed increase in perioperative complications
from neoadjuvant CRT